Human medicines European public assessment report (EPAR): Levetiracetam Sun, levetiracetam, Date of authorisation: 14/12/2011, Revision: 22, Status: Authorised

5 January 2026

Human medicines European public assessment report (EPAR): Jalra, vildagliptin, Date of authorisation: 19/11/2008, Revision: 26, Status: Authorised

5 January 2026

Human medicines European public assessment report (EPAR): Alymsys, bevacizumab, Date of authorisation: 26/03/2021, Revision: 10, Status: Authorised

5 January 2026

Human medicines European public assessment report (EPAR): Junod, denosumab, Date of authorisation: 23/06/2025, Revision: 1, Status: Authorised

5 January 2026

Human medicines European public assessment report (EPAR): Telzir, fosamprenavir, Date of authorisation: 12/07/2004, Revision: 48, Status: Withdrawn

5 January 2026

Human medicines European public assessment report (EPAR): Granupas (previously Para-aminosalicylic acid Lucane), para-aminosalicylic acid, Date of authorisation: 07/04/2014, Revision: 13, Status: Withdrawn

5 January 2026

Human medicines European public assessment report (EPAR): Kefdensis, denosumab, Date of authorisation: 17/11/2025, Status: Authorised

5 January 2026

Human medicines European public assessment report (EPAR): Zvogra, denosumab, Date of authorisation: 17/11/2025, Status: Authorised

5 January 2026

Human medicines European public assessment report (EPAR): Xiliarx, vildagliptin, Date of authorisation: 19/11/2008, Revision: 25, Status: Authorised

5 January 2026

Human medicines European public assessment report (EPAR): Trazimera, trastuzumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

5 January 2026